Quit Tobacco:
| Your Path to Quitting Smoking click text |
| Free Help to Quit Smoking click text |
| You can quit smoking now! click text |
| Dept. of Veterans Affairs offers "Quit Smoking" info and help here: http://www.publichealth.va.gov/smoking/quit_smoking.asp |
| Painting by ACAS Advisory Board member Albert Ortiz |
| "You can call it what you want — smokeless tobacco, spit tobacco, snus, chew, snuff, pinch, plug or dip — but don't call it harmless. If you're considering making the switch from cigarettes to chewing tobacco because you think the smokeless version of tobacco won't hurt you, be forewarned — chewing tobacco also causes serious health problems. Find out why chewing tobacco is not a healthy option." click here - Mayo Clinic Staff |
Please make your tax deductible donation to: Arizonans Concerned About Smoking, Inc.
Note: All contributions to the work of ACAS, Inc. are fully tax deductible as ACAS, Inc. is a 501C3 Corporation
Please copy, paste and print the following:
| -------------------------------------------------------------------------------------------------------------------------- Here is my tax deductible contribution to ACAS of: [ ]$25 [ ]$50 [ ]$100 [ ]$500 [ ]$1,000 [ ]Other $________________ Name _______________________________________________________________ Address_____________________________________________________________ City ______________________________ State ______ Zip ___________________ Make checks payable to: Arizonans Concerned About Smoking 525 W. Southern, Suite 109, Mesa, AZ, 85210 (480) 733-5864 E-mail: acasinc@msn.com www.acasinc.org -------------------------------------------------------------------------------------------------------------------------- |
ETR is proud to present a dynamic line of scientifically proven, field-tested tobacco prevention and cessation resources from Herb
Severson, PhD, a nationally acclaimed leader in tobacco education.
Developed through grants from the National Institutes of Health, all materials were subjected to rigorous peer review and evaluation.
You won’t find a more effective ally in your fight against smoking and smokeless tobacco.
Severson, PhD, a nationally acclaimed leader in tobacco education.
Developed through grants from the National Institutes of Health, all materials were subjected to rigorous peer review and evaluation.
You won’t find a more effective ally in your fight against smoking and smokeless tobacco.
| Purchase educational materials concerning: Abstinence, Alcohol & Other Drugs,Behavioral Health, Birth Control, Common Conditions, Disease Management, HealthSmart, HIV & Safer Sex, Maternal & Child Health, Men's & Women's Health, School Health, STD, Tobacco, Violence Weight, Nutrition & Fitness |
| For technical issues or errors, please contact webmasterACAS@live.com | Philip Carpenter |
| ACAS / Arizona News | USA / World News | Casinos | Fraternal / Service Clubs | In Cars w/ Kids | Multi-Unit Housing |
| Calendar | ACAS Officers | Health Pioneer Biographies | Tobacco Cessation | Health Links | Contact Us |
| Our Purpose Is To Save Lives |
525 W Southern Ave. Suite #109 Mesa, AZ 85210 | ph: 480.733.5864 | fax: 480.733.1844 | ACASinc@msn.com
Calendar | ACAS Officers | Health Pioneer Biographies | Tobacco Cessation | Health Links | Contact Us
ACAS / Arizona News | USA / World News | Casinos | Fraternal / Service Clubs | In Cars w/ Kids | Multi-Unit Housing
Smokefree Reports:
Resources for You
Click logo above for federal resources to help you quit using tobacco and to help you learn more about youth tobacco prevention,
effective treatment for nicotine addiction, and tobacco research and statistics.
Click logo above for federal resources to help you quit using tobacco and to help you learn more about youth tobacco prevention,
effective treatment for nicotine addiction, and tobacco research and statistics.
Personalized approach to smoking cessation may be reality in 3-5 years
| EurekAlert! | Contact: Debbe Geiger Debbe.Geiger@duke.edu | 919-660-9461 | Duke University Medical Center |
DURHAM, N.C. — (Public release date: 2-Jul-2010) A personalized approach to smoking cessation therapy is quickly taking shape.
New evidence from Duke University Medical Center and the National Institute on Drug Abuse (NIDA) suggests that combining
information about a smoker's genetic makeup with his or her smoking habits can accurately predict which nicotine replacement
therapy will work best.
"Within three to five years, it's conceivable we'll have a practical test that could take the guesswork out of choosing a smoking-
cessation therapy," says Jed Rose, Ph.D., director of Duke's Center for Nicotine and Smoking Cessation Research. "It could be used
by clinicians to guide the selection of treatment and appropriate dose for each smoker, and hopefully increase cessation success
rates."
Statistics show 70 percent of the nation's 46 million smokers say they want to quit, yet successfully kicking the habit has not proven
easy. In previously published reports, less than five percent of smokers who tried to quit on their own without any aids were not
smoking one year later. Long-term quit rates for smokers who relied on pharmacological intervention hover under 25 percent.
The research, which is published online in the July-August issue of Molecular Medicine, follows previous work done by Rose and
George Uhl, MD PhD, chief of the molecular neurobiology research at NIDA. After conducting a genome-wide scan of 520,000
genetic markers taken from blood samples of smokers in several quit-smoking trials, they identified genetic patterns that appear to
influence how well individuals respond to specific smoking cessation treatments.
New evidence from Duke University Medical Center and the National Institute on Drug Abuse (NIDA) suggests that combining
information about a smoker's genetic makeup with his or her smoking habits can accurately predict which nicotine replacement
therapy will work best.
"Within three to five years, it's conceivable we'll have a practical test that could take the guesswork out of choosing a smoking-
cessation therapy," says Jed Rose, Ph.D., director of Duke's Center for Nicotine and Smoking Cessation Research. "It could be used
by clinicians to guide the selection of treatment and appropriate dose for each smoker, and hopefully increase cessation success
rates."
Statistics show 70 percent of the nation's 46 million smokers say they want to quit, yet successfully kicking the habit has not proven
easy. In previously published reports, less than five percent of smokers who tried to quit on their own without any aids were not
smoking one year later. Long-term quit rates for smokers who relied on pharmacological intervention hover under 25 percent.
The research, which is published online in the July-August issue of Molecular Medicine, follows previous work done by Rose and
George Uhl, MD PhD, chief of the molecular neurobiology research at NIDA. After conducting a genome-wide scan of 520,000
genetic markers taken from blood samples of smokers in several quit-smoking trials, they identified genetic patterns that appear to
influence how well individuals respond to specific smoking cessation treatments.
The latest research focuses on combining the information from those individual genetic markers, called SNPs, into one number that
represents a "quit success score," Rose says. The score and the smokers' nicotine dependence, assessed via a simple
questionnaire, help predict an individual's likelihood of quitting, as well as whether a high-dose or low-dose nicotine patch would
work best.
In the trial, 479 cigarette smokers who smoked at least 10 cigarettes per day and wanted to quit were categorized as either high- or
low-dependence based on their level of nicotine dependence. The smokers in each group were then randomly assigned to wear two
nicotine skin patches daily delivering a high dose ( (42mg) or a standard dose (21 mg). Patches were worn for two weeks prior to
their quit date, and the nicotine doses were reduced gradually over the 10 weeks following their quit date. Participants were given
represents a "quit success score," Rose says. The score and the smokers' nicotine dependence, assessed via a simple
questionnaire, help predict an individual's likelihood of quitting, as well as whether a high-dose or low-dose nicotine patch would
work best.
In the trial, 479 cigarette smokers who smoked at least 10 cigarettes per day and wanted to quit were categorized as either high- or
low-dependence based on their level of nicotine dependence. The smokers in each group were then randomly assigned to wear two
nicotine skin patches daily delivering a high dose ( (42mg) or a standard dose (21 mg). Patches were worn for two weeks prior to
their quit date, and the nicotine doses were reduced gradually over the 10 weeks following their quit date. Participants were given
denicotinized cigarettes during the two weeks before the quit date to minimize any potential adverse effects from the high dose
nicotine patches. The treatment phase lasted for 12 weeks in all.
DNA was extracted from participants' blood and was used to assess a quit-smoking success genetic score.
At six months follow up, the researchers were able to confirm which smokers fared better or worse on the high-dose compared to the
low-dose patch.
"The genotype score was part of what predicted successful abstinence. In the future such a score could help us make our initial
treatment decisions," said Rose. "People who had both high nicotine dependence and a low or unfavorable quit success genetic
score seemed to benefit markedly from the high-dose nicotine patch, while people who had less dependence on nicotine did better
on the standard patch."
Further studies are needed to replicate these results, and to expand the research to include therapies like verenicline (Chantix,
Pfizer) and bupropion hydrochloride (Zyban, Glaxo SmithKline). But the potential this work holds for the future is significant, Rose
says.
"Right now there is no treatment algorithm that tells a clinician or smoker which treatment is likely to work for them," says Rose.
That's what we are trying to do. We want to tailor and give informative guidance to clinicians in terms of what should be tried first to
maximize smoking cessation success."
nicotine patches. The treatment phase lasted for 12 weeks in all.
DNA was extracted from participants' blood and was used to assess a quit-smoking success genetic score.
At six months follow up, the researchers were able to confirm which smokers fared better or worse on the high-dose compared to the
low-dose patch.
"The genotype score was part of what predicted successful abstinence. In the future such a score could help us make our initial
treatment decisions," said Rose. "People who had both high nicotine dependence and a low or unfavorable quit success genetic
score seemed to benefit markedly from the high-dose nicotine patch, while people who had less dependence on nicotine did better
on the standard patch."
Further studies are needed to replicate these results, and to expand the research to include therapies like verenicline (Chantix,
Pfizer) and bupropion hydrochloride (Zyban, Glaxo SmithKline). But the potential this work holds for the future is significant, Rose
says.
"Right now there is no treatment algorithm that tells a clinician or smoker which treatment is likely to work for them," says Rose.
That's what we are trying to do. We want to tailor and give informative guidance to clinicians in terms of what should be tried first to
maximize smoking cessation success."
| This study was the result of a collaboration between an investigator supported by the National Institutes of Health (NIH) Intramural Research Program, National Institute on Drug Abuse, and Duke University researchers who received a grant from Philip Morris USA. The company had no role in the planning or execution of the study, data analysis or publication of results. Disclosure: Drs. Uhl and Rose are listed as inventors for a patent application filed by Duke University based on genomic markers that distinguish successful quitters from unsuccessful quitters in data from other clinical trials. |
Consequences of Smokeless Tobacco Thanks to Jim Williams, Health Educator Phoenix Indian Medical Center |
| Arizona Smoke-Free History | additional Secondhand Smoke Kills! coverage | |